These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15909030)

  • 1. [Marketing--alendronate versus risedronate].
    Høiseth A
    Tidsskr Nor Laegeforen; 2005 May; 125(10):1386. PubMed ID: 15909030
    [No Abstract]   [Full Text] [Related]  

  • 2. [Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
    Praxis (Bern 1994); 2004 Sep; 93(36):1454. PubMed ID: 15487859
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [To increase bone density faster and stronger].
    MMW Fortschr Med; 2005 May; 147(18):44-5. PubMed ID: 15934589
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [FACT study: benefits of alendronate].
    MMW Fortschr Med; 2005 Jan; 147(1-2):52-3. PubMed ID: 15704574
    [No Abstract]   [Full Text] [Related]  

  • 7. [Osteoporosis therapy. Bisphosphonates compared].
    MMW Fortschr Med; 2003 Mar; 145(13):60. PubMed ID: 15101545
    [No Abstract]   [Full Text] [Related]  

  • 8. [Etidronate versus alendronate].
    Eriksen EF
    Tidsskr Nor Laegeforen; 1998 Feb; 118(6):949-50. PubMed ID: 9543818
    [No Abstract]   [Full Text] [Related]  

  • 9. Once-a-week alendronate (Fosamax).
    Med Lett Drugs Ther; 2001 Mar; 43(1100):26. PubMed ID: 11257718
    [No Abstract]   [Full Text] [Related]  

  • 10. Periodontal assessment of postmenopausal women receiving risedronate.
    Palomo L; Bissada NF; Liu J
    Menopause; 2005; 12(6):685-90. PubMed ID: 16278611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclical alendronate treatment in postmenopausal women with osteoporosis.
    Köşüş A; Capar M; Köşüş N
    Int J Gynaecol Obstet; 2005 Nov; 91(2):182-4. PubMed ID: 16098978
    [No Abstract]   [Full Text] [Related]  

  • 12. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
    [No Abstract]   [Full Text] [Related]  

  • 13. [Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
    Kruse HP
    MMW Fortschr Med; 2001 Nov; 143(47):33-6. PubMed ID: 11791359
    [No Abstract]   [Full Text] [Related]  

  • 14. Once-a-week risedronate (actonel).
    Med Lett Drugs Ther; 2002 Oct; 44(1141):87-8. PubMed ID: 12381968
    [No Abstract]   [Full Text] [Related]  

  • 15. [Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
    MMW Fortschr Med; 2005 Apr; 147(14):44. PubMed ID: 15887685
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
    Yanik B; Bavbek N; Yanik T; Inegöl I; Kanbay M; Turgut FH; Uz E; Akçay A
    Ren Fail; 2007; 29(4):471-6. PubMed ID: 17497471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E; Karalok H; Tufekci EC; Batur O
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates.
    Diez-Perez A
    Maturitas; 2002 Aug; 43 Suppl 1():S19-26. PubMed ID: 12361885
    [No Abstract]   [Full Text] [Related]  

  • 20. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
    Allen MR; Iwata K; Phipps R; Burr DB
    Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.